Amylyx Pharmaceuticals (AMLX) Stock Forecast & Price Target
Score
Amylyx Pharmaceuticals, Inc. price target
| AMLX | |
|---|---|
| Low | $42.00 |
| Average | $52.20 |
| High | $57.00 |
| Upside vs current price | +72.3% |
The average target of $52.20 is +72.3% versus the current AMLX price of $30.29.
Amylyx Pharmaceuticals, Inc. analyst ratings
| Rating | Analysts |
|---|---|
| Strong buy | 0 |
| Buy | 11 |
| Hold | 1 |
| Sell | 0 |
| Strong sell | 0 |
| Consensus | Buy |
12 analysts cover AMLX.
Amylyx Pharmaceuticals, Inc. EPS and revenue estimates
AMLX shows the next fiscal years with at least three analysts: 2026 EPS $-1.50, 2027 EPS $-1.13. A thinner year is left off this table.
| Fiscal year | EPS estimate | Revenue estimate |
|---|---|---|
| 2026 | $-1.50 | $80,625 |
| 2027 | $-1.13 | $56.55M |
Is Amylyx Pharmaceuticals, Inc. a buy or sell?
Of the 12 analysts covering Amylyx Pharmaceuticals, Inc., 11 rate it a buy (0 strong buy and 11 buy), 1 rates it a hold, and 0 rate it a sell (0 sell and 0 strong sell).
The AMLX consensus label is Buy, beside 11 buy-side ratings and 0 sell-side ratings.
The average target of $52.20 implies +72.3% versus the current price of $30.29.
Those 12 ratings on AMLX are a headcount, and the label on file is Buy.
Reading the Amylyx Pharmaceuticals, Inc. forecast
The AMLX target band runs from $42.00 to $57.00. The average inside that band is $52.20.
Set next to the $30.29 AMLX quote, that average is +72.3%.
Ratings on the Amylyx Pharmaceuticals, Inc. cluster: 11 of 12 analysts are on the buy side, 1 is at hold, and 0 are on the sell side, and the published consensus is Buy.
The AMLX EPS path from 2026 ($-1.50) to 2027 ($-1.13) is rising.
Only 12 analysts cover AMLX, so the average rests on a short list.
Amylyx Pharmaceuticals, Inc. forecast questions
What is the AMLX price target?
The published range for AMLX is $42.00 to $57.00, with an average of $52.20. That average is +72.3% versus the current price of $30.29.
Is Amylyx Pharmaceuticals, Inc. a buy or sell?
Of the 12 analysts covering Amylyx Pharmaceuticals, Inc., 11 rate it a buy, 1 rates it a hold, and 0 rate it a sell. The consensus is Buy, and the AMLX headcount is 11 buy, 1 hold, and 0 sell.
What is the EPS estimate for Amylyx Pharmaceuticals, Inc.?
Analyst EPS estimates for Amylyx Pharmaceuticals, Inc.: 2026 $-1.50, 2027 $-1.13.
What is the revenue estimate for Amylyx Pharmaceuticals, Inc.?
Analyst revenue estimates for Amylyx Pharmaceuticals, Inc.: 2026 $80,625, 2027 $56.55M.
How many analysts cover AMLX?
12 analysts cover AMLX. Their consensus on AMLX is Buy, across those 12.